SCOPE FLUIDICS SA ZY-10 - Asset Resilience Ratio
SCOPE FLUIDICS SA ZY-10 (S84) has an Asset Resilience Ratio of 32.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how SCOPE FLUIDICS SA ZY-10's Asset Resilience Ratio has changed over time. See SCOPE FLUIDICS SA ZY-10 (S84) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down SCOPE FLUIDICS SA ZY-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SCOPE FLUIDICS SA ZY-10 (S84) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €63.77 Million | 32.55% |
| Total Liquid Assets | €63.77 Million | 32.55% |
Asset Resilience Insights
- Very High Liquidity: SCOPE FLUIDICS SA ZY-10 maintains exceptional liquid asset reserves at 32.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SCOPE FLUIDICS SA ZY-10 Industry Peers by Asset Resilience Ratio
Compare SCOPE FLUIDICS SA ZY-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Access Bio Inc
KQ:950130 |
Diagnostics & Research | 12.52% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
Annual Asset Resilience Ratio for SCOPE FLUIDICS SA ZY-10 (2023–2025)
The table below shows the annual Asset Resilience Ratio data for SCOPE FLUIDICS SA ZY-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.55% | €63.77 Million ≈ $74.56 Million |
€195.94 Million ≈ $229.07 Million |
+19.71pp |
| 2024-12-31 | 12.84% | €22.19 Million ≈ $25.94 Million |
€172.87 Million ≈ $202.10 Million |
-7.76pp |
| 2023-12-31 | 20.60% | €20.90 Million ≈ $24.44 Million |
€101.49 Million ≈ $118.65 Million |
-- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.